NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2013

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include the addition of new regimens as options for salvage therapy and strategies to mitigate the adverse effects and risks associated with newer regimens for the treatment of multiple myeloma.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for multiple myeloma
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for multiple myeloma
Additional information
Supporters: 

Supported by educational grants from ARIAD Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.; CELGENE CORPORATION; Eisai Inc.; Endo Pharmaceuticals and HealthTronics; Genentech; Millennium: The Takeda Oncology Company; and Teva Pharmaceuticals

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
01/11/2013
Course expires: 
01/11/2014
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.